CLAIMS

1. A compound, represented by the following formula



Compound **1**

or pharmaceutically acceptable salt thereof.

2. A compound, represented by the following formula



Compound **2**

or pharmaceutically acceptable salt thereof.

3. A pharmaceutically acceptable salt of Compound **1** according to claim 1, which is selected from Compound **1** fumarate, Compound **1** napsylate, and Compound **1** edisylate.

4. A solid anhydrous form of Compound **1**.

5. The solid anhydrous form of Compound **1** according to claim 4, which is characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 7.3, about 9.6, about 11.1, about 12.0, about 12.7, and about 16.2 degrees 2-theta ± 0.2 degrees 2-theta.

6. The solid anhydrous form of Compound **1** according to claim 4 or 5, which is characterized in that it has a monoclinic crystal system and a $P2_1$ space group and/or the following parameters of its unit cell:

a	7.457 Å		**α**	90.0°
b	15.982 Å		**β**	90.0°
c	18.246 Å		**γ**	90.0°
V	2174.5 Å^3			

7. A pharmaceutical composition comprising a compound, pharmaceutically acceptable salt, or solid anhydrous form thereof according to any one of claims 1 to 6, and a pharmaceutically acceptable excipient.

8. Use of a compound, pharmaceutically acceptable salt, or solid form thereof according to any of claims 1 to 6, or a pharmaceutical composition according to claim 7, in the manufacture of a medicament for treating cancer and/or tumours in a patient, wherein said medicament is to be administered to the patient.

9. The use according to claim 8, wherein the medicament is to be administered in combination with radiotherapy.

10. The use according to claim 8, wherein the medicament is to be administered in combination with a DNA-damaging agent.

11. The use according to any of claims 8 to 10, wherein the tumour is selected from the group of diseases of squamous epithelium, bladder, stomach, kidneys, head, neck, oesophagus, cervix, thyroid, intestine, bone, liver, brain, prostate, urogenital tract, lymphatic system, larynx, lung, skin, blood and immune system, and/or wherein the cancer is selected from monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma, intestinal carcinoma, breast carcinoma, acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia, chronic lymphatic leukaemia, Hodgkin's lymphoma and non-Hodgkin's lymphoma.

12. Use of a compound, pharmaceutically acceptable salt, or solid anhydrous form thereof according to any of claims 1 to 6, in the manufacture of a medicament for the treatment of cancer and/or tumours according to any of claims 8 to 11.

13. Compound, pharmaceutically acceptable salt or solid form thereof according to any of claims 1 to 6, for use in the treatment of cancer and/or tumours, optionally in combination with radiotherapy and/or a DNA-damaging agent.